Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on ORIC Pharmaceuticals (NASDAQ: ORIC)The analyst comments "ORIC announced positive P1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE